Medical News Podcast

Joshua Solomon, MD and Jeff Swigris, DO discuss ILDs, a group of conditions marked by lung inflammation and fibrosis. They explore classifications, common causes, and advancements in understanding of these disorders to support effective diagnosis and management.

This discussion emphasizes the importance of risk mitigation strategies and practical tips for implementing oral immunotherapy (OIT) in clinical practice. Key points include ensuring adult supervision during dosing, adhering to safe dosing rules to minimize allergic reactions, and maintaining close communication with healthcare providers for adjustments or emergencies. The conversation highlights...

A study in Neurology links high intake of processed red meat to an increased risk of dementia and cognitive decline, with dietary changes showing protective effects. Research in the Journal of Arthroplasty highlights that COVID-19 infection within six weeks before knee surgery significantly raises the risk of venous thromboembolism. Wearable devices, such as Apple Watch and Fitbit, can predict inf...

In this discussion, Dr. Anagnostou and Dr. Greenhot review key elements for informed consent in oral immunotherapy (OIT), emphasizing the benefits, risks, and outcomes of the treatment. They highlight OIT's ability to increase allergen tolerance thresholds, while acknowledging potential risks like dose-related reactions and rare conditions such as eosinophilic gastrointestinal disorders. Alternati...

Aikaterini Anagnostou, MD (Hons), MSc, PhD and Matthew Greenhawt, MD, MBA, MSc discuss the process of preparing patients for oral immunotherapy (OIT). This first part of a 3-part video highlights the development and findings of the first International Delphi Consensus Panel on preparing patients for oral immunotherapy (OIT). Experts created a standardized checklist and consent framework to guide c...

Tejas Patil, MD and Sami Diab, MD discuss the pivotal role HER2 positivity plays in lung cancer including the challenges faced by clinicians in testing for HER2. They discuss topics in sequencing, next generation testing, and liquid biopsies as well as challenges of testing in tissue-efficient manner.

Drs. Isaacs and Traina share insights from the 2024 San Antonio Breast Symposium, covering the MARGOT trial, survival impacts of risk-reducing surgeries in young BRCA carriers, and outcomes of delaying surgery in operable breast cancer.

Claudine Isaacs, MD and Tiffany A. Traina, MD, FASCO share their insights from the 2024 San Antonio Breast Cancer Symposium on the TOUCH trial, DTP trial, and data on SHR-A1811 in HER2+ early breast cancer.

In this episode, a study shows that private equity acquisition of hospitals is linked to declines in patient care experience, with significant drops in ratings and staff responsiveness. The episode also discusses a strong link between hearing loss and increased risk of Parkinson’s disease, suggesting that early auditory health management may play a role in mitigating symptoms. Finally, U.S. medica...

Drs. Komrokji and Kuykendall review the evolution of clinical trial endpoints in myelofibrosis studies. They discuss traditional measures of disease control, such as spleen volume reduction and hematologic response, as well as expanded endpoints that reflect the biological and symptomatic aspects of myelofibrosis.

In this episode, smoking one cigarette shortens life expectancy by an average of 20 minutes, with 17 minutes for men and 22 minutes for women, as shown by data from Britain. Also in this bpodcast, brief vigorous activity, like climbing stairs or carrying groceries, can lower cardiovascular risks, with just 3.4 minutes daily reducing major events by 45%. Finally, advances in cancer prevention, scre...

Andrew Kuykendall, MD and Rami Komrokji, MD discuss cytopenic myelofibrosis, reviewing how these patients typically present. They also cover mutational burden, specific treatment strategies, and prognosis in patients with the cytopenic phenotype.

Dr. Angela Fleischman and Dr. Gabriella Hobbs discussed two intriguing abstracts presented at the ASH 2024 Annual Meeting about emerging treatments for myelofibrosis. The first study, led by Dr. Lucia Massarova, explored the safety and preliminary efficacy of cord blood-derived CXCR4-enriched T-regulatory cells in patients with suboptimal response to ruxolitinib, showing minimal adverse events and...

Drs. Coombs and Shadman review CLL abstracts presented at the ASH 2024 annual meeting, including results from 2 early‑phase evaluations of BTK degraders and primary results of the ibrutinib combination cohort from the TRANSCEND CLL 004 study of the CAR T‑cell therapeutic, liso‑cel.

In this episode of the Peer Direct Specialist Spotlight, Gabriella Hobbs, MD and Angela Fleischman, MD, PhD discuss updates from the ASH 2024 annual meeting on emerging therapies for myelofibrosis, focusing on two agents: ilritracept and PXS-5505. Ilritracept, a modified ligand trap, showed promise in improving anemia, transfusion burden, spleen size, and symptoms, with data suggesting potential b...

A JAMA study identified factors linked to loss to follow-up in diabetic retinopathy and macular edema patients, including male gender, distance from care, and sociodemographic disparities. In Vietnam, six months of levofloxacin therapy showed a non-significant reduction in multidrug-resistant tuberculosis, emphasizing the balance between benefits and tolerability. Finally, Phase II trial showed pa...

Mazyar Shadman, MD, MPH and Catherine C. Coombs, MD review CLL abstracts presented at the ASH 2024 annual meeting, including results from the BRUIN CLL‑321 study of pirtobrutinib in relapsed or refractory CLL and the AMPLIFY study of first‑line acalabrutinib plus venetoclax.

Children raised on farms or with pets appear to have a lower risk of allergies due to early gut microbiota differentiation, as highlighted by a study from the Farm Flora Birth Cohort. Managing food allergies durin travel remains challenging, with a global survey showing inconsistent airline policies and unmet preventive measures. FDA trials indicate that resistance to Paxlovid in mild to moderate...

A Korean study found that anaphylaxis recurrence, affecting 15.6% of cases, is driven by socioeconomic factors and comorbidities, calling for targeted interventions. Australian data revealed a sharp rise in melanoma-related deaths for tumors 0.8–1.0 mm thick, suggesting a need for stricter monitoring and management for these patients. Lastly, the experimental drug BNC210 showed early promise in re...

Research from JAMA Dermatology suggests that ultra-processed foods may exacerbate psoriasis by promoting systemic inflammation and disrupting the gut microbiome, with potential benefits seen in dietary changes. A study presented at the Radiologic Society of North America revealed that transgender women face significantly higher injury rates, underscoring the need for better screening for intimate...

In the first episode of this two-part series, Elizabeth Kensinger, PhD and Andrew Budson, MD explore the science of memory, aging, and dementia. They discuss how memory encompasses a wide range of abilities and is influenced by factors like stress, lifestyle, and neurological health, highlighting differences in memory issues between younger adults, depression, and Alzheimer’s disease. The conversa...

John Mascarenhas, MD and Kathryn Johnson, DNP, MSc, FNP‑BC discuss the common signs and symptoms seen in patients with myelofibrosis and share insights into how they go about addressing them. They review anemia and splenomegaly, platelet-related symptoms of bleeding and thrombosis, and constitutional symptoms.

Dr. Mascarenhas and Kathryn Johnson review important considerations for referring physicians in clinical trials for myelofibrosis. They cover timing for referral, referral pathways, and appropriate patients, as well as assessments, monitoring, and even logistical considerations.

In 2023, measles cases rose 20% globally and immunization rates fell far below the 95% threshold needed to prevent outbreaks. A promising nasal spray therapy targeting neuroinflammation shows potential to delay Alzheimer’s progression by 10–15 years, according to a study leveraging neural stem cell-derived extracellular vesicles. Additionally, a phase 1 trial of neoantigen DNA vaccines in triple-n...

Drs. Clayton and Payne review the burden of PPD, highlighting the importance of early and effective treatment. They explore the impact of PPD on not only postpartum patients, but also on infants, families, and society as a whole.